IQVIA (IQV) Stock Price, Fundamentals & Analysis

What IQV does

IQVIA (IQV) is a US stock in the Healthcare sector, specifically the Diagnostics & Research industry, headquartered in Durham, United States. It provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries across the Americas, Europe, Africa, and Asia-Pacific. The company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Key numbers explained

• 267.86 USD is the current price, which is up 49% over the last 52 weeks, within a range of 154.5 – 277.4.
• The trailing P/E ratio of 33.3 shows how much investors pay per dollar of past earnings; the forward P/E ratio of 18.5 reflects the same based on expected future earnings.
• Earnings per share (trailing 12 months) is 8.05 USD, meaning the company earned that amount per share over the last year.
• The dividend yield is 0%, and 0% of earnings are paid out as dividends, meaning the company currently does not distribute cash to shareholders.
• Beta of 1.19 indicates the stock is slightly more volatile than the overall market.
• Return on equity of 22.8% measures how effectively the company generates profit from shareholders' equity.
• The debt-to-equity ratio of 258% means the company has more debt than equity, which is common in large, capital-intensive industries.
• Price-to-book of 7.14 compares the market price to the company's book value per share.

Recent news

Recent headlines indicate that IQVIA issued $2 billion in notes, prompting analysis of whether the stock looks fairly valued. Other coverage highlights a strong rebound in the stock, with one piece noting a 60% rise over six months, while Morgan Stanley adjusted its price target to $270 from $240, maintaining an Equalweight rating.

What to watch

Investors tracking IQV may consider its position within the S&P 500 and compare it to peers like Charles River Laboratories (CRL) and Regeneron Pharmaceuticals (REGN). Key factors include the upcoming earnings date of 3 nov. 2026, the company's revenue growth of 8.7% year over year, and its profit margin of 8.1%. Broader healthcare sector trends, interest rate environments, and clinical trial activity can also influence the stock's performance.